(: )

Last Updated: Sep-26-2016 09:56:05

PCYC News & Stock Updates

  • Celebrate This High-Profit Milestone with Some More Triple-Digit Gains

    This was the very first stock we recommended on the very first day Private Briefing was published – Aug. 11, 2011.

    On that day, you could've owned it for less than nine bucks a share – $8.60.

    That's a distant memory.

    We've re-recommended these shares more than a dozen times since then, so successive "classes" of our readers can participate in these gains.

    And sure enough, this stock hit an all-time high at midday yesterday… up a whopping 717% from that first day we wrote about it.

    Let me tell you the ticker - and why I think there's a lot more profit in store for this "classic" pick...
  • Biotech Boom: (Nasdaq: ABBV), (Nasdaq: PCYC), (NYSE: JNJ)

    Shares of AbbVie Inc. (Nasdaq: ABBV) slipped more than 5% this morning on news that the pharmaceutical giant will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for $21 billion. The deal will give AbbVie access to the very promising blood cancer drug, Imbruvica, although Johnson & Johnson (NYSE: JNJ) currently receives half of the drug's revenue thanks to […]

  • Seven Biotech Stocks to Watch Based on "Game-Changing" Cancer Treatment Updates

    A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) – which is why this is a key time of year to watch a specific group of biotech stocks.

    The event, which this year took place May 30 – June 3, is attended by thousands of renowned oncologists, researchers, analysts, and investors. It is unquestionably the most highly anticipated and most news-generating cancer research meeting of the year.

    ASCO can deliver a blockbuster, breakout drug that will not only lead to better cancer treatments, but one that will also bring in billions of dollars in revenue. Moreover, there's also the potential of a drug's developer becoming a profitable takeover target.

    Check out this list of biotech stocks to watch post-ASCO.

Premium Research

(: ) Profile

Prior Close$
Market Cap$0 B
PE Ratio
Please contact customer service about our stock charts

PCYC Earnings

1st Quarter Earnings$ ()
2nd Quarter Earnings$ ()
3rd Quarter Earnings$ ()
4th Quarter Earnings$ ()
PE Ratio
EPS Growth0%
Recent Earnings$
Annual EPS$
Market Capitalization$0 B
Insider Shareholder %0%
Annual Revenue$0 B
Number of Shares Outstanding0 Shares
Institutional Shareholder %0%
Annual Net Income$0B
TTM Net Profit Margin$0
One Year Return%
Three Year Return%
Five Year Return%
Five Year Revenue Growth%
Five Year Earnings Growth%
Five Year Dividend Growth%
Last Quarter EPS$
Annual EPS$
Annual Dividend$0
Annual Dividend Yield%
Change in EPS YTD%
PE Ratio
Recent Earnings$
Dividends per Share$
Stock Split Ratio

PCYC Key Stats

Last Price$
Net Change$ (%)
Ask Price$
Open Price$
Previous Close Price$
High Price$
Low Price$
Number of Trades0
Fifty Two Week High$ ()
Fifty Two Week Low$ ()
Average Daily Volume0
Share Outstanding0 Shares
Total Dividend Payout$/yr
Dividend Yield%